background
lung
transplant
patient
experi
high
risk
airway
infect
microbi
colon
lung
due
constant
exposur
environ
inhal
microorgan
denerv
reduc
ciliari
transport
decreas
cough
method
nationwid
prospect
studi
swedish
lung
transplant
patient
evalu
microbiolog
panorama
bacteria
fungi
viru
found
bronchoalveolar
lavag
fluid
balf
obtain
first
year
lung
transplant
ltx
differ
microbiolog
find
depend
concomit
sign
infect
background
factor
assess
result
total
bronchoscopi
patient
evalu
sixtytwo
percent
n
balf
sampl
posit
microbiolog
find
fortysix
percent
n
bacteri
growth
n
fungal
growth
n
posit
viral
pcr
balf
sampl
n
singl
microb
found
wherea
combin
bacteria
fungi
viru
found
n
bronchoscopi
common
microbiolog
find
candida
albican
pseudomona
aeruginosa
coagulas
neg
staphylococcu
patient
respect
microbiolog
find
similar
balf
patient
without
sign
lung
infect
frequenc
multidrug
resist
mdr
bacteria
low
signific
associ
found
background
factor
time
first
lung
infect
conclus
studi
give
import
epidemiolog
insight
reinforc
microbiolog
find
evalu
light
clinic
symptom
endobronchi
appear
assess
lung
infect
lung
transplant
patient
k
e
w
r
bronchoalveolar
lavag
fluid
lung
infect
lung
transplant
microbiolog
lung
transplant
ltx
increas
treatment
option
end
stage
lung
diseas
although
mortal
post
transplant
decreas
modern
surgic
techniqu
pharmaceut
regim
mortal
report
around
infect
predomin
caus
death
first
year
post
ltx
constant
exposur
environ
inhal
microorgan
togeth
denerv
reduc
ciliari
transport
decreas
cough
increas
risk
lung
infect
moreov
heavi
immunosuppress
therapi
lead
decreas
exclud
patient
follow
year
transplant
written
inform
consent
obtain
studi
particip
studi
approv
region
ethic
committe
reg
nr
perform
accord
ethic
standard
declar
helsinki
later
amend
standard
protocol
immunosuppress
includ
induct
therapi
atg
antithymocyt
globulin
follow
tacrolimu
ciclosporin
mycophenol
mofetil
steroid
lung
transplant
recipi
receiv
pneumocysti
prophylaxi
cotrimoxazol
cytomegaloviru
cmv
prophylaxi
valganciclovir
given
particip
except
patient
gothenburg
donor
recipi
cmv
neg
lund
patient
receiv
fungal
prophylaxi
fluconazol
month
wherea
patient
gothenburg
receiv
oral
nystatin
least
week
standard
periop
antibiot
treatment
cefotaxim
gothenburg
imipenem
lund
postop
modif
termin
antibiot
treatment
done
accord
periop
donor
recipi
cultur
ltx
procedur
bacteri
fungal
cultur
obtain
donor
recipi
lung
recipi
follow
first
year
ltx
routin
bronchoscopi
month
post
transplant
addit
bronchoscopi
perform
respons
clinic
symptom
bal
proce
bronchoscopi
posit
microbiolog
find
classifi
pneumonia
presenc
least
one
follow
clinic
criteria
new
increas
cough
dyspnea
increas
sputa
fever
worsen
ga
exchang
white
blood
cell
count
l
togeth
new
within
day
bronchoscopi
infiltr
chest
radiolog
xray
ct
scan
bronchoscopi
posit
microbiolog
find
classifi
tracheobronch
presenc
clinic
sign
infiltr
chest
radiolog
one
follow
macroscop
endobronchi
abnorm
inflam
endobronchi
clinic
data
record
time
bronchoscopi
studi
protocol
retriev
retrospect
patient
record
time
transplant
categor
month
month
month
month
ltx
microbiolog
find
group
gramneg
bacteria
gramposit
bacteria
g
yeast
mold
viru
p
aeruginosa
analyz
separ
numer
data
present
median
rang
chisquar
rank
sum
kruskallw
test
logist
regress
analysi
varianc
use
assess
distribut
background
factor
among
differ
bacteri
group
lung
infect
time
period
sinc
particip
underw
vari
number
bronchoscopi
studi
sever
patient
recurr
find
pathogen
balf
frequenc
individu
microb
report
total
number
patient
actual
find
group
microbiolog
find
first
year
present
percent
patient
bronchoscopi
within
specifi
time
period
contrast
overal
microbiolog
find
lung
infect
present
number
episod
proport
patient
associ
background
data
gender
age
ltx
type
ltx
underli
diseas
type
immunosuppress
posit
neg
donor
cultur
time
first
lung
infect
estim
cox
regress
statist
test
twosid
ci
overlap
pvalu
less
consid
statist
signific
analys
perform
use
total
patient
elig
inclus
consecut
includ
studi
nine
patient
unabl
give
inform
consent
one
patient
declin
particip
one
patient
includ
unknown
reason
nine
patient
die
bronchoscopi
perform
result
patient
gothenburg
lund
prospect
follow
year
ltx
particip
median
age
year
women
underw
doubl
lung
transplant
chronic
obstruct
pulmonari
diseas
copd
common
underli
diseas
detail
patient
characterist
see
tabl
total
balf
sampl
neg
microbiolog
result
includ
sampl
growth
pharyng
flora
singl
n
doubl
n
underli
diagnosi
n
patient
chronic
obstruct
pulmonari
diseas
pulmonari
fibrosi
cystic
fibrosi
antitrypsin
defici
pulmonari
arteri
hypertens
retransplant
bronchiol
obliteran
syndrom
figur
exclud
analys
remain
proport
patient
bacteri
find
balf
increas
first
month
declin
figur
yeast
common
within
first
month
ltx
wherea
mold
peak
month
figur
proport
viral
find
increas
time
maximum
patient
month
figur
lung
transplant
procedur
bacteri
fungal
cul
wish
thank
staff
transplant
bronchoscopi
author
conflict
interest
declar
relat
materi
present
asa
plan
studi
compil
data
perform
statist
calcul
wrote
manuscript
accord
editori
polici
ethic
consider
author
revis
materi
discuss
result
contribut
final
manuscript
anna
aspelund
http
